Dr. Shannon Westin on PARP Inhibition for Ovarian Cancer

Published: Thursday July 20, 2017

Dr. Westin is a clinical investigator with a focus on developmental therapeutics and the use of biomarkers to predict response and recurrence in gynecologic cancers. Her background in public health, with a focus on clinical investigation and epidemiology, has provided her with a clear understanding of the study design and validation techniques which are essential to the study of these topics. She is the principal investigator of several novel treatment trials for endometrial cancer as well as a Phase I trial of agents relevant to ovarian cancer.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication